- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CYXONE Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 3,866 | +2,49 % | Valneva Aktie: 2 Euro oder 8 Euro - wo liegen die nächsten Ziele? | Die Valneva Aktie hat turbulente Jahre mit einem Kurssturz auf 1,726 Euro hinter sich gebracht. Der Aktienkurs des französischen Impfstoff-Entwicklers befindet sich seit Ende 2024 aber wieder in einer... ► Artikel lesen | |
| NOVAVAX | 6,061 | +4,99 % | Novavax, Inc.: Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights | Total revenue of $70 million in the third quarter of 2025
Continued successful execution of Sanofi partnership with $225 million in milestones achieved year-to-date... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 1,700 | -2,86 % | COSCIENS Biopharma Inc. Announces Leadership Change | TORONTO, ONTARIO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) ("COSCIENS" or the "Company"), a life science company focused on natural ingredients and pharmaceutical... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 1,040 | +0,48 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762 | Nonclinical protocol study design accepted by FDA Study to commence in First Quarter 2026King of Prussia, Pennsylvania--(Newsfile Corp. - December 23, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:... ► Artikel lesen | |
| ORAGENICS | 0,815 | +4,62 % | Oragenics Q2 2025 Shareholder Update | Advancing Brain-First Recovery Platform Toward Clinical MilestonesPioneering Intranasal Therapeutics for Concussion SARASOTA, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American:... ► Artikel lesen | |
| ARGENX | 728,20 | +1,65 % | $100 Invested In argenx 5 Years Ago Would Be Worth This Much Today | ||
| LEXICON PHARMACEUTICALS | 1,022 | +1,49 % | Lexicon Pharmaceuticals, Inc.: Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum | THE WOODLANDS, Texas, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced clinical data on adipose tissue distribution in non-diabetic patients treated with sotagliflozin... ► Artikel lesen | |
| OUTLOOK THERAPEUTICS | 0,589 | -65,56 % | Outlook Therapeutics, Inc.: Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA (bevacizumab-vikg) for the Treatment of Wet AMD | ISELIN, N.J., Dec. 31, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of... ► Artikel lesen | |
| CSTONE PHARMACEUTICALS | 0,570 | 0,00 % | CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES THE INCLUSION OF GAVRETO (PRALSETINIB) IN THE 2025 NATIONAL REIMBURSEMENT DRUG LIST | ||
| GENSCRIPT BIOTECH | 1,439 | -1,24 % | GenScript Biotech Corporation: GenScript Biotech Demonstrates Profitable Scale and Strategic Leadership in H1 2025, Establishing Clear Industry Leadership Through Accelerated Growth and Innovation | Rising Global Footprint, Best-in-Class Innovation, and ESG Excellence Set Stage for Sustained Value Creation
PISCATAWAY, N.J., Aug. 17, 2025 /PRNewswire/ --... ► Artikel lesen | |
| SERES THERAPEUTICS | 12,540 | -1,10 % | Seres Therapeutics, Inc.: Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155 | CAMBRIDGE, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that CARB-X (Combating Antibiotic-Resistant Bacteria... ► Artikel lesen | |
| KRYSTAL BIOTECH | 204,70 | -5,58 % | Krystal Biotech: Gentherapie-Pionier vor neuen Hochs? | Die Aktie von Krystal Biotech hat in den vergangenen Monaten stark an Dynamik gewonnen und notiert fast auf ihrem Allzeithoch aus 2024. Die Erwartungen an das Unternehmen bleiben hoch, doch mit dem... ► Artikel lesen | |
| ALIGOS THERAPEUTICS | 7,900 | -3,66 % | Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results | SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, "Aligos"), a clinical stage biotechnology company focused on improving patient outcomes through... ► Artikel lesen | |
| Q32 BIO | 2,660 | -0,75 % | Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update | -- Completed enrollment in Part B of SIGNAL-AA Phase 2a clinical trial and increased trial size to 33 patients based on patient demand; topline data readout expected... ► Artikel lesen | |
| XENETIC BIOSCIENCES | 2,150 | 0,00 % | Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting | Adjourns 2025 Annual Meeting of StockholdersUrges Stockholders Who Have Not Voted To Get Votes In FRAMINGHAM, MA / ACCESS Newswire / December 11, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic"... ► Artikel lesen |
Das Unternehmen CYXONE AB kann der Branche Biotechnologie zugeordnet werden.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CYXONE AB finden Sie auf Wallstreet Online.